Kiniksa Pharmaceuticals International, Earnings Call Transcripts
Fiscal Year 2026
-
ARCALYST continues to drive strong revenue growth and market penetration in recurrent pericarditis, with patients typically remaining on therapy for a median of three years. The company is advancing its pipeline with KPL-387 in phase III and expanding outreach through targeted education and DTC campaigns.
-
Q2 2026 saw ARCALYST revenue surge 55% year-over-year to $243.6 million, driving a guidance raise to $980–995 million for the year. The pivotal phase III trial for KPL-387 began enrollment, supported by strong phase II data, while cash reserves grew to $525.9 million.
-
Strong commercial growth and expanded guidance for ARCALYST are supported by increasing prescriber adoption and a shift to chronic disease management. Pipeline assets KPL-387 and KPL-1161 are advancing, with key clinical milestones expected in 2024, and the company remains financially robust and focused on innovation.
-
Strong Q1 growth led to raised 2026 revenue guidance for ARCALYST, with expanding physician adoption and ongoing efforts to increase patient awareness. Pipeline progress includes KPL-387 phase II data expected in H2 and KPL-1161 entering phase I by year-end. Cash reserves remain robust at $468 million.
-
Q1 2026 saw ARCALYST revenue rise 56% year-over-year to $214.3M, driving net income to $22.6M and prompting a raised full-year revenue outlook. Strong commercial execution, new prescriber growth, and targeted DTC campaigns support continued momentum.
-
Revenue grew 62% in 2025, driven by increased patient adds, prescriber expansion, and longer therapy duration, with only 18% market penetration so far. Pipeline progress includes upcoming Phase II data for KPL-387 and a Phase I start for KPL-1161, while disciplined capital allocation supports ongoing growth.
-
Significant revenue growth and market expansion were highlighted, with ARCALYST now established as the second-line standard of care for recurrent pericarditis. Pipeline progress includes KPL-387 in phase 2/3 trials and KPL-1161 entering the clinic by year-end, supporting a robust outlook.
Fiscal Year 2025
-
ARCALYST revenue surged 62% year-over-year to $677.6 million in 2025, with net income turning positive and strong cash generation. Pipeline progress continues with KPL-387 and KPL-1161, and 2026 revenue guidance is set at $900–$920 million.
-
ARCALYST continues robust growth with increased early adoption and strong 2025 revenue guidance. KPL-387, a monthly IL-1 inhibitor, advances in phase 2/3 trials, with high physician and patient interest and potential launch by 2028–2029.
-
Q3 2025 saw ARCALYST revenue surge 61% year-over-year to $180.9 million, driving a net income of $18.4 million and prompting a raised full-year sales guidance to $670–$675 million. Market adoption and prescriber growth remain strong, with KPL-387 advancing in development.
-
ARCALYST continues strong revenue growth with expanded prescriber base and increased patient duration, while new Medicare Part D policies provided a one-time boost. Pipeline programs KPL-387 and 1161 are advancing, with KPL-387 showing high physician and patient interest. Cash flow remains positive as development and commercialization efforts progress.
-
ARCALYST continues robust growth with strong revenue, expanding prescriber base, and high compliance. New guidelines and real-world data support its use, while KPL-387’s monthly dosing profile is poised to further expand the market. Innovation and global expansion remain strategic priorities.
-
Q2 net revenue rose 52% year-over-year to $156.8 million, driven by ARCALYST's strong commercial performance and expanded prescriber base. 2025 sales guidance was raised to $625–$640 million, and the KPL-387 Phase 2/3 trial is underway with data expected next year.
-
Strong ARCALYST growth and increased prescriber engagement drove higher 2024 revenue guidance and Q1 profitability. Medicare Part D redesign improved patient affordability, while pipeline assets KPL-387 and KPL-1161 advance, supporting long-term growth and lifecycle management.
-
Profitability and strong ARCALYST growth have enabled increased 2025 revenue guidance and robust cash reserves. KPL-387 is advancing with a phase II/III trial starting mid-2025, targeting a 2028–2029 launch. Education and broad payer coverage support further market expansion.
-
Q1 2025 net revenue rose 75% year-over-year to $137.8M, with net income of $8.5M and strong cash flow. Raised 2025 Arcalyst sales guidance to $590–$605M, driven by increased prescriber adoption, longer therapy duration, and Medicare Part D changes.
-
The conference highlighted robust commercial growth, with ARCALYST achieving $416.4M in 2024 revenue and strong guidance for 2025. Strategic expansion, innovative clinical programs, and a shift in treatment paradigms position the company for continued success.
Fiscal Year 2024
-
Q4 and full year 2024 saw robust ARCALYST revenue growth and strong cash flow, with 2025 guidance projecting further gains. The company advanced KPL-387 for monthly dosing in recurrent pericarditis and discontinued abiprubart in Sjogren's disease to focus on core assets.
-
ARCALYST continues to grow in market penetration and duration of therapy, supported by expanded field efforts and increased disease awareness. The phase II-B study of abiprubart in Sjögren’s disease is progressing, with a strong financial position and openness to new business opportunities.
-
ARCALYST continues robust growth with expanding prescriber base, high payer approval, and increasing treatment duration. The addressable market may grow as earlier-stage patients are targeted, while pipeline progress and disciplined business development support future value creation.
-
Q3 2024 saw 73% year-over-year ARCALYST revenue growth to $112.2M, with increased prescriber adoption and repeat use. Full-year sales guidance was raised to $410–$420M, and the company remains cash flow positive with a strong financial position.
-
ARCALYST continues to drive steady growth in recurrent pericarditis, with increasing physician adoption, a shift to steroid-sparing management, and expanding patient identification. The pipeline asset abiprubart is advancing in Sjögren's, with differentiated dosing and potential for broader autoimmune indications.
-
Q2 2024 saw 90% year-over-year ARCALYST revenue growth, increased market penetration, and a raised full-year sales outlook to $405–$415 million. The company advanced abiprubart into Phase 2b for Sjögren’s disease and maintained strong cash reserves.
-
ARCALYST continues robust growth with 9% market penetration and strong compliance, supported by expanded field teams and patient programs. Pipeline progress includes a phase IIb trial in Sjögren's and ongoing business development, all underpinned by a strong cash position and disciplined capital allocation.